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Rheumatoid arthritis (RA) is an autoimmune joint disease maintained by aberrant immune responses
involving CD4+ T helper (Th)1 and Th17 cells. In this study, we tested the therapeutic efficacy of
Ligand Epitope Antigen Presentation System (LEAPSTM) vaccines in two Th1 cell-driven mouse models
of RA, cartilage proteoglycan (PG)-induced arthritis (PGIA) and PG G1-domain-induced arthritis (GIA).
The immunodominant PG peptide PG70 was attached to a DerG or J immune cell binding peptide, and
the DerG-PG70 and J-PG70 LEAPS vaccines were administered to the mice after the onset of PGIA or
GIA symptoms. As indicated by significant decreases in visual and histopathological scores of arthritis,
the DerG-PG70 vaccine inhibited disease progression in both PGIA and GIA, while the J-PG70 vaccine
was ineffective. Splenic CD4+ cells from DerG-PG70-treated mice were diminished in Th1 and Th17
populations but enriched in Th2 and regulatory T (Treg) cells. In vitro spleen cell-secreted and serum
cytokines from DerG-PG70-treated mice demonstrated a shift from a pro-inflammatory to an anti-
inflammatory/regulatory profile. DerG-PG70 peptide tetramers preferentially bound to CD4+ T-cells of
GIA spleen cells. We conclude that the DerG-PG70 vaccine (now designated CEL-4000) exerts its thera-
peutic effect by interacting with CD4+ cells, which results in an antigen-specific down-modulation of
pathogenic T-cell responses in both the PGIA and GIA models of RA. Future studies will need to determine
the potential of LEAPS vaccination to provide disease suppression in patients with RA.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disorder charac-
terized by chronic inflammation and systemic destruction of the
peripheral joints [1–6]. RA is a very heterogeneous disease that
may have different initiators and be driven by different types of
inflammatory responses for each individual. Although the initiat-ing events of RA are unknown, the disease is maintained by
pro-inflammatory mediators produced during T helper (primarily
Th1 and Th17) cell-driven autoimmune responses [1].
Current treatment of RA largely focuses on alleviation of symp-
toms and delaying disease progression [7]. The two primary treat-
ment modalities are synthetic, small molecule disease-modifying
anti-rheumatic drugs (sDMARDs), and biologic large molecule
DMARDs (bDMARDs) [8]. Both sDMARDs and bDMARDS suppress
elements of the entire immune system in order to curtail the
inflammatory process.
The pro-inflammatory cytokine interleukin (IL)17 has become a
popular target for treating the inflammation associated with RA.
IL17-targeting therapies still only treat the symptoms, do not act
on the source of the inflammatory pathways, are not disease- or
antigen-specific, and may ablate important anti-microbial immune
responses [6,9].
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with either sDMARDs or bDMARDs and has the potential to modu-
late the different cells and cytokines involved in the ongoing
autoimmune and inflammatory responses. In contrast to other
therapies for RA, therapeutic vaccines focus on the antigen specific
disease-driving cells that are upstream of disease presentation to
modulate the pro-inflammatory Th1 or Th17 responses or enhance
regulatory T-cell (Treg) responses in a beneficial manner [10]. A
key advantage of therapeutic vaccination is antigen specificity,
which is focused on the disease initiators, but the vaccine must
also modulate the aberrant ongoing immune reactions of the
patient.
LEAPS3 (Ligand Epitope Antigen Presentation System) vaccines
offer the opportunity to immunize with a disease-related antigen
and concurrently modulate the subsequent immune response. LEAPS
vaccines are heteroconjugate peptides composed of a disease-
specific antigenic epitope and an immune cell binding ligand
(ICBL)[10]. The J peptide ICBL is from human b2 microglobulin and
acts first on dendritic cells (DC) [11–13] and the DerG peptide from
domain 2 of the b chain of the human MHC class II (HLA-DR) mole-
cule acts on CD4+ T cells [14–16].
The LEAPS vaccine CEL-2000 (a conjugate composed of a J ICBL
and an immunodominant type II collagen (CII) epitope) was shown
to be therapeutic when administered after the onset of disease
symptoms in collagen induced arthritis (CIA), a Th17-driven mouse
model of RA [17]. The therapeutic effect was accompanied by
reduced serum levels of pro-inflammatory cytokines. Other
J-LEAPS heteroconjugate vaccines were effective in treating exper-
imental autoimmune myocarditis [18] or viral infections in animal
models [11,12,19,20].
Proteoglycan (PG)-induced arthritis (PGIA) and G1 domain (of
PG) induced arthritis (GIA) are autoimmune animal models of
RA,3 induced by intraperitoneal (i.p.) immunization of BALB/c
female mice with PG of human articular cartilage [21] or the
recombinant G1 domain (rhG1) of PG [22]. Both the PGIA and
GIA models are predominantly driven by Th1 interferon-gamma
(IFNc) responses [22–25], and generate Th17 as well as other
pro- and anti-inflammatory cytokines responses. The PGIA
[21,26] and GIA [22] models resemble human RA better than other
animal models.
We report here the results of testing J-LEAPS (J-PG70) and
DerG-LEAPS (DerG-PG70, also called CEL-4000) vaccines, hetero-
conjugates with the PG70 peptide,3 in the PGIA and GIA models
of RA. The effects of vaccines on the disease process, joint
histopathology, and serum levels of anti-inflammatory and pro-
inflammatory cytokines were evaluated. T-cell phenotypes and
production of cytokines were also examined in vitro using spleen
cells from vaccinated and control diseased animals. Binding of
vaccine component peptides to different types of immune cells
was examined to identify cells likely involved in the response to
the vaccines.2. Materials and methods3
2.1. Peptides
The sequences of thepeptidesused for the in vivoand in vitro stud-
ies were as follows: PG70 (ATEGRVRVNSAYQDK), DerG (DGQEE
KAGVVSTGLIGGG), J (DLLKNGERIEKVEGGG), and conjugates DerG-
PG70 (DGQEEKAGVVSTGLIGGGATEGRVRVNSAYQDK) and J-PG70
(DLLKNGERIEKVEGGGATEGRVRVNSAYQDK). Peptides were pur-
chased from 21st Century Biochemicals (Marlborough, MA) or
Ambiopharm (North Augusta, SC) at 95% purity with amino acid3 For related information see Supplementary Information.sequences and mass confirmed by mass spectrometry. Biotinylated
peptides were purchased from Biomatik, Inc. (Wilmington, DE).
2.2. Antigens used for inducing arthritis
Human cartilage PG and rhG1 protein were prepared as
described.3
2.3. Mice, immunization, and visual assessment of arthritis
Adult (retired breeder) female BALB/c mice were obtained from
the National Cancer Institute (NCI; Frederick, MD) or from the for-
mer NCI facility acquired by Charles River (Wilmington, MA).
To induce PGIA, mice were immunized i.p. with human PG
(100 lg protein in 100 ml sterile phosphate-buffered saline (PBS,
pH 7.2)) [21,26] emulsified in dimethyl-dioctadecyl ammonium
bromide adjuvant (DDA; Sigma-Aldrich, St Louis, MO) three times,
three weeks apart [25]. Mice were inspected for signs of arthritis
(swelling and redness) twice a week after the second PG immu-
nization. Upon disease onset, the degree of arthritis for each paw
was visually scored every other day on a scale of 0 to 4 for each
limb, summing the individual paw scores to a maximum visual
arthritis (VA) score of 16 per animal3 [25,27].
Similarly, groups of mice were immunized with rhG1 (40 mg per
injection in DDA) i.p. three times to induce GIA [22]. The limbs of
animals with GIA were visually scored for the degree of arthritis
3 times a week as described for PGIA.3
2.4. Vaccine treatment of mice with PGIA or GIA
Vaccine treatment was initiated after the mice developed
arthritis (PGIA or GIA). Briefly, mice with a similar average VA
score in each group (ranging from 2 to 4 in the different studies)
were sorted into treatment groups. Doses (100 nmol) of LEAPS con-
jugates or individual peptides were prepared in 100 ml sterile PBS
(pH 7.2) and emulsified at a 1:1 ratio with Montanide ISA-51VG
adjuvant (Seppic, Paris, France). The vaccines (or control PBS in
adjuvant) were administered s.c. at the nape of the neck into anes-
thetized mice. The mice were treated first on the day of initial
grouping (day 0) and the same dose was administered s.c. on day
14. Monitoring of the VA scores continued three weeks after the
second vaccination.3
2.5. Collection of blood and tissues from mice
At the end of the experiments, mice were anesthetized, and
bled. Serum samples were stored at 70 C until use. After blood
draw, the anesthetized mice were euthanized via CO2 inhalation.
Spleens were harvested under aseptic conditions for in vitro
studies, and hind limbs excised and fixed in formalin. All animal
procedures3 were approved by the Institutional Animal Care and
Use Committee (IACUC) of Rush University Medical Center (IACUC
permit number: 14-032).
2.6. Histology
Hind limbs tissue sections were prepared, processed, examined,
photographed and scored as described3 [21,25–27].
2.7. Spleen cell cultures
Single cell suspensions from the spleens of mice with PGIA or
GIA were processed as described.3 The spleen cells were seeded
into 48-well culture plates (3  106 viable cells per well) in the
absence or presence of PG (50 mg/ml) or rhG1 (7.5 mg/ml) for cells
from PGIA and GIA mice, respectively, and cultured for 4 days.
ig. 1. Visual arthritis (VA) scores of mice with PGIA or GIA treated with LEAPS
onjugate vaccines or control agents. VA scores of mice in the (A) initial PGIA study
tudy 1), (B) initial GIA study (Study 2) and (C) confirmatory GIA study (Study 3)with
dditional control groups (dotted lines). VA Scoring: sum of value for each paw: 0 = no
vidence of inflammation, 1 = slight swelling of the paw or at least 3 finger joints,
= moderateswellingof thepawandfingers, 3 = moderateswellingof thepaw,fingers,
nd ankle/wrist joints, 4 = severe swelling and redness of paw, fingers, and ankle/wrist
ints, summing the individual paw scores to a maximum VA score of 16 per animal
4–38]. Groups ofmice (n = 8–9mice per group) with VA scores averaging3 in each
roupwere injected s.c. on day 0 (black arrowswith squares) and day 14 (black arrows
ith diamonds) with the following: (A) and (B) PBS emulsified with Seppic ISA-51VG
djuvant (solid green lines, vehicle control), J-PG70 in PBS + adjuvant (solid orange
nes), orDerG-PG70 inPBS + adjuvant (solid blue lines). (C)Groups treated as shown in
) and (B) and the three additional control groupswere treatedwith PBS (no adjuvant)
ottedgray line), PG70 inPBS + adjuvant (dottedbrownline)orDerGinPBS + adjuvant
otted blue line). Data are expressed as the mean ± SEM. Asterisks depict statistically
gnificant (*p < 0.05) differences between the DerG-PG70-treated and PBS + adjuvant)
ontrol groups. Data were analyzed using (two-way repeated measures analysis of
ariance ANOVA with post hoc Fisher’s least significant differences (LSD) test). (For
terpretationof the references to color in thisfigure legend, the reader is referred to the
eb version of this article.)
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cytometry
The percentages of Th (CD4+) spleen cells containing intracellu-
lar cytokines or Foxp3 in cultures of antigen-stimulated spleen
cells were determined by flow cytometry [28] on a BD FACS Canto
II flow cytometer and analyzed using FACS Diva software (BD Flow
Cytometry Systems, San Jose, CA).3
2.9. Assays of in vitro cytokine secretion
For cytokine secretion studies, spleen cells were either left
untreated (native cultures) or treated with human PG or rhG1 (for
PGIA and GIA cells, respectively) as specified above. On the fourth
day of culture, the plates were centrifuged, supernatants were col-
lected and frozen at 70 C. For the PGIA study, the concentrations
of cytokines were determined by ELISA (IFNc, IL17, IL4, IL10 kits
(Peprotech, Rocky Hill, NJ) and transforming growth factor (TGFb1;
R & D Systems, Minneapolis, MN), according to the manufacturers’
instructions. For the GIA studies, multiple cytokinesweremeasured
using the multi-plex mouse Th17 kit (IL1b, IL2, IL4, IL6, IL10,
IL12p70, IL17A, IL17F, IFNc, TNFa) or a single-plex kit for TGFb1
(both from EMDMillipore, Billerica, MA), according to themanufac-
turer’s instructions and analyzed using a MagPix reader with
MilliPlex Analyst software (both from EMD Millipore).3
2.10. Serum cytokine assays
Cytokine levels in the serum samples of GIA mice were mea-
sured using the MagPix technology as described above for cell
culture supernatants.
2.11. Generation of bone marrow-derived dendritic cells (BM-DCs)
BM was obtained from naïve mice and was enriched in DCs as
described previously [28,29]. DCs (MHC class II+ CD11c+ cells) con-
stituted over 60% of the collected cell population, as determined by
flow cytometry [29].3
2.12. Assay of peptide tetramer binding to cells
The avidity of peptide binding was increased by tetramerization
of biotinylated (B)-peptides with streptavidin-phycoerythrin (SA-
PE) according to a protein tetramerization protocol provided by
the National Institutes of Health (NIH) Tetramer Core Facility
(Emory University, Atlanta, GA). Peptide binding to cells was
detected by flow cytometry as described.3
2.13. Statistical analysis
The GraphPad Prism 6 software (GraphPad, La Jolla, CA) was
used for both statistical analysis and plotting of data. Results are
presented as mean ± SEM. The statistical tests used as well as other
details are provided in the Figure Captions and in the footnote to
Table 1. P values less than 0.05 were accepted as statistically signif-
icant (Material handling and data collection details as described).3
3. Results
3.1. DerG-PG70 LEAPS vaccine limits arthritis progression in vivo
3.1.1. Visual arthritis (VA) scores
The therapeutic activities of LEAPS vaccines containing Der-G-
PG70 or J-PG70 peptide conjugates (emulsified with Seppic ISA-
51VG adjuvant) were compared to controls containing vehicle
(PBS with or without adjuvant), in the PGIA (Fig. 1A: Study 1)F
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Table 1
Histopathology scores of the hind limbs of mice with GIA following in vivo treatment with LEAPS peptide vaccines or control agents.1
GIA (Study 2)2 GIA (Study 3)2
PBS + adj. J-PG70 + adj. DerG-PG70 + adj. PBS + adj. J-PG70 + adj. DerG-PG70 + adj. PG70 + adj. DerG + adj. PBS
Inflammation 4.70 ± 0.1 4.00 ± 0.9 3.45 ± 0.6 4.56 ± 0.2 5.00 ± 0.0 2.97 ± 0.6⇑,# 3.72 ± 0.6 4.88 ± 0.1 4.50 ± 0.2
Pannus formation 1.00 ± 0.0 0.80 ± 0.2 0.65 ± 0.1⇑ 1.38 ± 0.2 2.13 ± 0.2 0.81 ± 0.2 1.13 ± 0.3 1.56 ± 0.1 1.38 ± 0.2
Cartilage damage 4.60 ± 0.2 3.95 ± 0.9 3.45 ± 0.6 3.84 ± 0.4 4.94 ± 0.1 2.34 ± 0.5# 3.41 ± 0.7 4.88 ± 0.1 4.13 ± 0.4
Bone resorption 1.00 ± 0.0 0.80 ± 0.2 0.65 ± 0.1⇑ 1.38 ± 0.2 2.06 ± 0.2 0.78 ± 0.2 1.13 ± 0.3 1.56 ± 0.1 1.38 ± 0.2
Periosteal bone formation 2.10 ± 0.0 2.10 ± 0.4 1.70 ± 0.3 1.94 ± 0.2 2.06 ± 0.1 1.19 ± 0.3 1.88 ± 0.4 2.06 ± 0.1 2.19 ± 0.2
Cumulative scores 13.40 ± 0.2 11.65 ± 2.6 9.90 ± 1.6 13.09 ± 1.0 16.13 ± 0.5 8.09 ± 1.8# 11.25 ± 2.1 14.94 ± 0.2 13.09 ± 1.0
1 Hind limbs of mice with rhG1-induced arthritis (GIA), treated with either LEAPS peptide vaccines in adjuvant (+adj.) or control agents, were subjected to joint
histopathology evaluation as described in the Materials and Methods. Scores of individual histopathology parameters (inflammation, pannus formation, etc.) and cumulative
scores identified as italized values are listed.
2 Values are the means ± SEM; n = 5 mice/group (Study 2) and n = 8 mice/group (Study 3). Data were transformed (Y = Y2) before statistical analysis using one-way ANOVA
followed by Fisher’s LSD test (Study 2) or by Dunnett’s test (Study 3) for multiple comparisons. The lowest individual and cumulative scores were noted in mice treated with
DerG-PG70 LEAPS vaccine in both studies. Statistically significant differences are indicated as:
⇑ p < 0.05 (DerG-PG70 + adj. vs. PBS + adj. control).
# p < 0.05 (DerG-PG70 + adj. vs. PBS control).
Fig. 2. Effects of LEAPS vaccines on the phenotype of cultured CD4+ T-cell
populations from the spleens of mice with (A) PGIA or (B) GIA. Percentages of
Th1 (IFNc+), Th17 (IL17+), Th2/Treg (IL10+), and CD25+ Tregs (Foxp3+) in PG-
stimulated cultures of spleen cells from control or LEAPS-vaccine treated PGIA or
GIA mice as determined by intracellular cytokine or Foxp3 staining and flow
cytometry. For culture conditions see Materials and Methods. Data shown are the
mean ± SEM of the percent of cytokine-expressing CD4+ T-cell populations in the
cultures from the 3 groups of PGIA mice (spleen cells from n = 4 per group) and GIA
mice (n = 8 per group). Data were analyzed in both (A) and (B) using one-way
ANOVA with Fisher’s LSD test. Asterisks depict statistically significant differences
(*p < 0.05).
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Study 3 (Fig. 1C), additional controls of peptides PG70 and DerG
in adjuvant as well as PBS without adjuvant were tested. As indi-
cated by the VA scores, treatment with the DerG-PG70 vaccine sig-
nificantly (⁄p < 0.05) limited disease progression within 3 weeks in
all three studies whereas J-PG70 or individual peptides had no sig-
nificant effects as compared with the PBS/adjuvant or PBS control
(Fig. 1). Importantly, the DerG-PG70 vaccine effectively curtailed
arthritis symptoms in GIA (Fig. 1B and 1C) despite its more aggres-
sive disease course compared to PGIA (Fig. 1A).
3.1.2. Histopathological changes
Histopathological changes in the joints, induced by autoim-
mune inflammatory damage, or as modulated by vaccine treat-
ment, were evaluated in comparison with normal joints of naïve
mice (see Supplementary Figs. 1 and 2).3
Table 1 shows the individual and cumulative histopathology
scores of the limbs of GIA mice (Study 2 and Study 3) after the ani-
mals underwent the in vivo treatments. In Study 2, mice treated
with DerG-PG70 in adjuvant had significantly (⁄p < 0.05) reduced
pannus formation and bone resorption as well as lower cumulative
histopathology scores as compared to controls treated with PBS in
adjuvant. In Study 3, DerG-PG70-treated animals demonstrated
significantly reduced degree of inflammation, cartilage damage,
and cumulative histopathology score, while J-PG70-treated mice
generally had greater joint damage than PBS/adjuvant-treated con-
trols. While the effect of DerG-PG70 on reduction of inflammation,
pannus formation, cartilage damage, bone resorption, periosteal
bone formation, or summed scores did not always reach the level
of statistical significance in Studies 2 and 3, a protective effect
was indicated by strong reductions in these parameters in both
studies (Table 1). The in vivo VA scores (Fig. 1) and joint
histopathology (Table 1 and Supplementary Figs. 1 and 2) indicate
that DerG-PG70 treatment of PGIA and GIA mice had a consistent
and reproducible therapeutic effect.
3.2. T-cell phenotypes of splenocytes from vaccine treated PGIA and
GIA mice
The phenotypes of CD4+ T-cells within the spleen cell cultures
of the treatment groups of PGIA and GIA mice were determined
by flow cytometric evaluation of intracellular cytokines IFNc
(Th1), IL17 (Th17), or IL10, or the Treg cell marker, Foxp3, following
in vitro stimulation with antigen (PG or rhG1). Treatment of PGIA
(Fig. 2A) or GIA (Fig. 2B) mice with the DerG-PG70 vaccine led to
a reduction of pro-inflammatory Th1 and Th17 cells (even afterantigen stimulation) and an increase in the frequency of anti-
inflammatory IL10-producing as well as protective Treg cells in
both models.
4052 K. Mikecz et al. / Vaccine 35 (2017) 4048–40563.3. In vitro secretion of cytokines by splenocytes from vaccine-treated
PGIA and GIA mice
Cytokine production from cell cultures prepared from the
spleens of vaccinated mice were measured to evaluate ongoing
or antigen-induced responses. Cytokine production by spleen cells
receiving no additional in vitro antigen stimulation represent cellu-
lar responses resulting from the combination of the effects of dis-
ease and vaccine treatments on the mice, whereas cytokine
production following in vitro antigen stimulation represents addi-
tional antigen-specific responses resulting from the combined
effects of disease, vaccination, and in vitro antigen treatment. We
specifically focused on the ratios of anti-inflammatory (IL4 or
IL10) to pro-inflammatory (IFNc or IL17) T-cell cytokines in the
spleen cell cultures of PGIA and GIA mice (Fig. 3) as calculated from
the concentrations of secreted cytokines (Supplementary Fig. 3).3
In the PGIA study, these ratios were significantly increased in favor
of anti-inflammatory cytokine release in both the non-stimulated
(Fig. 3A) and PG-stimulated (Fig. 3B) spleen cell cultures of DerG-
PG70-treated mice as compared to PBS/adjuvant-treated controls.
In the GIA study, the IL4:IL17(A + F) ratio was significantly
increased in the in vitro non-stimulated (Fig. 3C), but not in the
rhG1-stimulated cultures (Fig. 3C). These ratios reflect the reduc-
tions in pro-inflammatory cytokines (IFNc and IL17(A + F)) and
increases in anti-inflammatory cytokines (IL4, TGFb, and IL10)Fig. 3. Ratios of key anti-inflammatory to pro-inflammatory T-cell cytokines in in vitro cu
(C and D) mice. Ratios of secreted anti-inflammatory (IL4 or IL10) to pro-inflammatory (
PGIA cultured in the absence of antigen (A) (in vitro non-stimulated cultures), or (B) in
cytokines in the supernatants of spleen cells from GIA mice cultured in the absence of a
(in vitro rhG1-stimulated cultures) (see Supplementary Fig. 31 for cytokine concentrations
control and LEAPS-treated groups were made using Fisher’s LSD test. Asterisks depict stdue to DerG-PG70 vaccine treatment, as compared to control treat-
ment in all the PGIA cultures, although the differences did not
always reach significance (Supplementary Figs. 3A and 3B).3 In
the cell cultures from GIA mice, DerG-PG70 vaccination resulted
in significant reductions in the production of IL17(A + F) and IFNc,
but other cytokines were affected to a lesser degree (Supplemen-
tary Fig. 3C and 3D).3
Differences in the results between the PGIA and GIA spleen cell
cytokine secretion studies may reflect differences in the detection
methods (i.e., ELISA versus MagPix with the latter being more
sensitive than the former), but it is more likely that they reflect dif-
ferences between the two animal models [22]. The relative inabil-
ity of the DerG-PG70 vaccine to suppress IFNc secretion by native
or rhG1-stimulated spleen cells from GIA mice as opposed to a sup-
pressive effect on IFNc production by PGIA spleen cells might be
due to the overproduction of IFNc in the GIA model compared to
the PGIA model, as demonstrated here and as reported previously
[22]. Ultimately, the pro-inflammatory response was reduced by
DerG-PG70 treatment in both models.
3.4. Serum levels of cytokines
Concentrations of 10 different cytokines (IL4, TNFa, IFNc, IL2,
IL1b, IL6, IL10, IL12p70, IL17A, and IL17F) in serum samples from
LEAPS-vaccinated and control GIA mice (Studies 2 and 3) wereltures of spleen cells from control and LEAPS vaccine-treated PGIA (A and B) and GIA
IL17 or IFNc) cytokines detected in the supernatants of spleen cells from mice with
the presence of PG antigen (in vitro PG-stimulated cultures). The ratios of the same
ntigen (C) (in vitro non-stimulated cultures) or (D) in the presence of rhG1 antigen
). Data were analyzed with one-way ANOVA and pairwise comparisons between the
atistically significant differences (*p < 0.05).
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the immune and inflammatory processes. In both GIA studies,
IL17F serum levels were significantly reduced in DerG-PG70-
treated mice as compared to the PBS/adjuvant-treated controls,
but the concentrations of other cytokines were comparable among
the treatment groups (Supplementary Fig. 4). Ratios of anti-
inflammatory T-cell cytokines (IL4 and IL10) to pro-inflammatory
T-cell cytokines (IL17(A + F) and IFNc) in serum from DerG-PG70
treated mice were significantly increased in favor of anti-
inflammatory responses (Fig. 4A and B).Fig. 4. Ratios of key anti-inflammatory to pro-inflammatory cytokines in serum
samples collected from control and LEAPS-treated GIA mice. Ratio of anti-
inflammatory IL4 (A) or IL10 (B) to pro-inflammatory IL17(A + F) in the sera of
GIA mice at the end of studies. Ratio of anti-inflammatory IL4 (C) or IL10 (D) to pro-
inflammatory IFNc in the sera of the same mice. Cytokine concentrations were
determined using a multiplex Luminex MagPix kit (serum concentrations of 10
different cytokines are shown in Supplementary Fig. 4).3 Results are expressed as
the mean ± SEM of cytokine ratios (n = 8 mice in Study 2 and n = 9 mice in Study 3
per group). Data analysis was performed using one-way ANOVA followed by
Fisher’s LSD test. Asterisks indicate statistically significant differences (*p < 0.05).3.5. Binding of LEAPS conjugates and related individual peptides to
immune cells in vitro
The binding of tetramers ofDerG-PG70, J-PG70, and their compo-
nent peptides to spleen cells from GIA mice and BM-derived DCs
from normal mice was examined in vitro to identify the cell types
that can be affected by treatment. SA-PE-B-Peptide tetramers were
prepared to increase the avidity and add fluorescence to the peptide
ligands to facilitate analysis of their binding to cells. Tetramerswere
formedwith SA-PEusingamethoddeveloped fordetecting thebind-
ing of MHC-peptide complexes to T-cells by flow cytometry [30].
However, as the LEAPS heteroconjugate peptides contained a cell
binding ligand (eitherDerGor J), addition ofMHCwasnot necessary.
Although the DerG-PG70 tetramer bound to CD4+ T-cells (Fig. 5A,
top)better than theother ligands, binding specificity to theother cell
typeswas relatively difficult to discern. Specifically, the binding pat-
terns to DCs were obscured by the high background fluorescence
(e.g., SA-PE alone), possibly due to phagocytic activity of DCs [31]
(Fig. 5A, bottom). Therefore, the net mean fluorescence intensity
levels (above the SA-PE background) were calculated as a measure
of specific peptide binding to cells (Fig. 5B). By comparing the bind-
ing ofDerG-PG70and J-PG70, two similar-sized peptides differing in
the ICBL, thebindingpreference of theDerG-PG70 tetramer for CD4+
T-cells was evident. Similarly, the binding preference of J-PG70 for
MHC II-bearing cells (APCs) and CD11c+ BM-DCs became evident.
Tetramers containing the individual peptides (PG70, DerG or J)
bound very weakly to all of the cell types examined (Fig. 5B).4. Discussion
Since Th1-dominated diseases might benefit from a shift away
from the pro-inflammatory Th1 to a more balanced Th2 or Treg
response, our hypothesis was that treatment with a Th2-
promoting DerG LEAPS heteroconjugate incorporating PG70 would
initiate an antigen specific response to ameliorate the arthritis
symptoms, while a Th1-promoting J-LEAPS heteroconjugate with
PG70 would either have no effect or exacerbate disease. Indeed,
the DerG-PG70 vaccine reproducibly curtailed the progression of
disease in PGIA and two independent GIA studies as indicated by
the VA scores of in vivo monitored animals and joint histopathol-
ogy. As expected, treatment with the J-PG70 vaccine was either
ineffective or slightly exacerbated disease in these models.
Although the outcomes in the two disease systems were similar,
there were differences in the kinetics of both disease development
and vaccine effects between PGIA and GIA.
As in RA, the inflammatory disease in both the PGIA and GIA
models is driven and sustained primarily by Th1 but also by
Th17 cells and cytokines produced by them. DerG-PG70 treatment
promoted more balanced, less inflammatory cytokine responses by
increasing Th2 (IL4+ and IL10+) and Treg (Foxp3+ and TGFb1+)
cells and reducing Th1 and Th17 cells in PGIA, and to a somewhat
lesser extent in the GIA system, as represented by the T-cell pheno-
types from the treated animals. The switch from a pro-
inflammatory T-cell population to one favoring regulation and
modulation by DerG-PG70 treatment in the spleen is likely to
reflect the systemic changes seen in the curtailed progression of
disease.
Although showing similar trends, the immune responses driv-
ing disease and subsequently, the responses to DerG-PG70 and J-
PG70 for the PGIA and GIA models were subtly different. There is
more robust production of IFNc in the GIA model compared to
the PGIA model, as seen herein and an earlier study [22]. In both
models, the therapeutic effect of DerG-PG70 treatment was
reflected in the reduction in IL17 production and the proportion
of Th17 cells, critical players in RA pathogenesis. The reduction
Fig. 5. Binding of LEAPS conjugates or individual peptides to cells in vitro as determined by flow cytometry. (A) Representative flow cytometry panels of streptavidin-
phycoerythrin (SA-PE)-biotinylated (B)-peptide tetramer binding to splenic CD4+ T-cells or APCs from GIA mice or to BM-DCs from naïve mice. Cells binding (SA-PE)-B-
peptide tetramer are shown as dots in the box within each of the flow panel frames. (B) Summary of (SA-PE)-B-peptide tetramer binding flow cytometry data using GIA spleen
cells (n = 8 mice) or BM-DCs from naïve mice (n = 6). Results are expressed as the means ± SEM of net mean fluorescence intensity (net MFI: total MFI minus SA-PE alone
background MFI). For statistical analysis, data were transformed (Y = Y2) and then analyzed using one-way ANOVA followed by Dunnett’s test for multiple comparisons.
Asterisks indicate statistically significant differences (*p < 0.05).
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K. Mikecz et al. / Vaccine 35 (2017) 4048–4056 4055in these pro-inflammatory responses was likely due to increases in
Th2 and/or Treg activity.
The ICBL component of a LEAPS vaccine attached to the disease
related antigenic peptide promotes interaction with immune cells
and hence directs the subsequent immune response. Using the SA-
PE-peptide tetramers it was possible to demonstrate that the
DerG-PG70 conjugate preferentially bound to splenic CD4+ Th (or
Treg) cells, whereas J-PG70 showed preference for binding to
MHC II-bearing APCs and CD11c+ DCs, known to be involved in
PGIA [32]. Preference for CD4+ T-cells is in keeping with previous
studies for the DerG ICBL peptide [10,13–16,33,34], and preference
for APCs for the J ICBL, is consistent with its ability to promote the
maturation of DCs [11,12,20]. The binding studies suggest that the
DerG-PG70 conjugate modulates T-cell responses via direct bind-
ing to CD4+ T-cells in the PGIA and GIA mice.
The ability of DerG-PG70 to steer T-cells away from pro-
inflammatory responses and promote anti-inflammatory/
regulatory activities explains the therapeutic success of DerG-
PG70 in restricting the progression of disease in the treated PGIA
and GIA mice. Unlike cytokine ablation [23,35], which also sup-
presses PGIA, DerG-PG70 appears to act directly on the T-cell dri-
vers of the immune response rather than the subsequently
elicited arthritis related cytokines to ameliorate disease progres-
sion. Focusing the therapy on the inflammatory disease-
promoting immune responses in an antigen-specific manner with
LEAPS vaccines appears to bring the system to an appropriate bal-
ance, presumably without loss of important immune protections.
RA is different for different patients and failure to respond to cer-
tain therapiesmay reflect differences in the initiators and responses
driving their disease. In this study, theDerG-PG70vaccinewas effec-
tive in curtailing progression of arthritis driven by Th1 responses
whereas a collagen peptide-containing J-LEAPS vaccine, CEL-2000,
was effective in blocking the progression of arthritis in the Th17-
driven CIA model [17]. As such, knowledge of signature T-cell cyto-
kine phenotypes that drive the patient’s disease can facilitate the
choice of the appropriate LEAPS vaccine therapy.5. Conflicts of interest
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